March 18th 2024
The use of ChatGPT may help to improve genetic counseling for patients with gynecologic cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Factors Influencing Treatment Post-Chemo in dMMR Endometrial Cancer
November 9th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Bradley Corr, MD, discussed the use of immune checkpoint inhibitors in patients with advanced endometrial cancer. This is the second of 2 articles based on this event.
Read More
Managing Adverse Events With Immune Checkpoint Inhibitors in Endometrial Cancer
November 5th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Paul A. DiSilvestro, MD, discussed with participants concerning the management of adverse events in a patient receiving single-agent immune checkpoint inhibitor for advanced mismatch-repair deficient endometrial cancer.
Read More
Dostarlimab Plus Chemo Betters OS in Endometrial Cancer
November 3rd 2023The combination of dostarlimab and chemotherapy demonstrated meaningful improvements in overall survival for the treatment of primary advanced or recurrent endometrial cancer, according to findings from the phase 3 RUBY trial.
Read More
Tisotumab Vedotin Shows Potential in Cervical Cancer With Disease Progression
October 27th 2023In an interview with Targeted Oncology, Brian Slomovitz, MD, details findings from the innovaTV 301 trial investigating tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer.
Read More
KEYNOTE-826 Data Confirm Survival Benefit of Pembrolizumab Addition in Cervical Cancer
June 16th 2023In an interview with Targeted Oncology, Bradley J. Monk, MD, FACCOG, FACS, highlighted final results from the phase 3 KEYNOTE-826 trial of pembrolizumab plus chemotherapy vs chemotherapy plus placebo, with or without bevacizumab in persistent, recurrent, or metastatic cervical cancer.
Read More